Reviewing Addex Therapeutics (NASDAQ:ADXN) and BetterLife Pharma (OTCMKTS:BETRF)

BetterLife Pharma (OTCMKTS:BETRF) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Volatility & Risk

BetterLife Pharma has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.

Institutional & Insider Ownership

0.0% of BetterLife Pharma shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 34.8% of BetterLife Pharma shares are held by insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares BetterLife Pharma and Addex Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BetterLife Pharma	N/A	N/A	-$1.07 million	N/A	N/A
Addex Therapeutics	$29,972.00	241.08	-$8.12 million	($5.94)	-0.99

BetterLife Pharma has higher earnings, but lower revenue than Addex Therapeutics.

Profitability

This table compares BetterLife Pharma and Addex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BetterLife Pharma	N/A	N/A	-772.34%
Addex Therapeutics	N/A	-134.76%	-106.00%

Analyst Ratings

This is a summary of recent recommendations for BetterLife Pharma and Addex Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BetterLife Pharma	0	0	0	0	0.00
Addex Therapeutics	1	0	0	0	1.00

Summary

Addex Therapeutics beats BetterLife Pharma on 5 of the 8 factors compared between the two stocks.

About BetterLife Pharma

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.